Repatha

MedCo's PCSK9 challenger steals the show at ESC with winning data
MedCo's PCSK9 challenger steals the show at ESC with winning data
Fierce Pharma
Medicines Company
ESC
PCSK9 inhibitors
inclisiran
Repatha
Praluent
European Society of Cardiology
Flag link:
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Sanofi, Regeneron score win against Amgen patents on PCSK9 med Repatha
Fierce Pharma
Sanofi
Regeneron
Amgen
PCSK9 inhibitors
patents
Praluent
Repatha
Flag link:
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Lackluster Amgen, Sanofi PCSK9 drugs could be under major threat from a new rival: analyst
Fierce Pharma
Amgen
Regeneron
Sanofi
Praluent
Repatha
Medicines Company
PCSK9 inhibitors
inclisiran
Flag link:
German court blocks sale of Sanofi, Regeneron cholesterol drug
German court blocks sale of Sanofi, Regeneron cholesterol drug
Biopharma Dive
patents
Amgen
Sanofi
Regeneron
Germany
Praluent
Repatha
Flag link:
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
Investors Business Daily
Amgen
Repatha
clinical trials
Flag link:
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Regeneron, Sanofi cut PCSK9 list price, matching earlier move by rival Amgen
Biopharma Dive
Regeneron
Sanofi
Amgen
Praluent
Repatha
drug pricing
PCSK9 inhibitors
Flag link:
Amgen touts lowered prices for Repatha delivery devices
Amgen touts lowered prices for Repatha delivery devices
Drug Delivery Business News
Amgen
drug delivery
Repatha
Flag link:
7 drugs that raised eyebrows in Q3
7 drugs that raised eyebrows in Q3
Biopharma Dive
Sanofi
Dupixent
Roche
Herceptin
AbbVie
Humira
Regeneron
Repatha
Clovis Oncology
Rubraca
GSK
Shingrix
Eli Lilly
Trulicity
Flag link:
In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%
In Unprecedented Move, Amgen Cuts Price Of Cholesterol Drug Repatha By 60%
Forbes
Amgen
Repatha
drug pricing
Flag link:
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Citing appeals court 'anarchy,' Amgen asks SCOTUS to weigh its PCSK9 patent spat with Sanofi
Fierce Pharma
Amgen
Sanofi
Regeneron
PCSK9 inhibitors
Supreme Court
Praluent
Repatha
Flag link:
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
Amgen's Repatha Reduces Bad Cholestrol in Type II Diabetes
NASDAQ.com
Amgen
Repatha
type 2 diabetes
diabetes
hypercholesterolemia
ADA
Flag link:
Are These Disappointing Drugs Back on Track to Billions?
Are These Disappointing Drugs Back on Track to Billions?
Motley Fool
PCSK9 inhibitors
Sanofi
Regeneron
Amgen
Praluent
Repatha
Flag link:
Amgen focuses on migraine launch as growth remains slow
Amgen focuses on migraine launch as growth remains slow
Biopharma Dive
Amgen
earnings
Repatha
Kyprolis
Prolia
Xgeva
Flag link:
Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Is Amgen’s Outcomes-Based Pricing Model for Repatha Benefiting Patients and Payers?
Xtalks
Amgen
Repatha
outcome-based pricing
drug pricing
patients
Flag link:
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
Amgen's money-back offer on Repatha isn't all that meaningful, researchers find
Biopharma Dive
Amgen
Repatha
Flag link:
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Amgen darkens the mood in new Repatha TV ads, warning of heart and stroke risks
Fierce Pharma
Amgen
Repatha
DTC ads
heart attack
stroke
Flag link:
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Amgen faces tough one-two blow as competition mounts for Repatha and Sensipar
Fierce Pharma
Amgen
Repatha
Sensipar
generics
Sanofi
Regeneron
Praluent
Flag link:
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
The Moment Of Truth Is Coming For Struggling And Expensive Cholesterol Drugs
Forbes
cholesterol
PCSK9 inhibitors
Sanofi
Regeneron
Praluent
Amgen
Repatha
Flag link:
What to Expect From Amgen, Inc. in 2018
What to Expect From Amgen, Inc. in 2018
Motley Fool
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
Flag link:
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Opdivo, Repatha and Lynparza likely among China’s 2018 blockbuster nods: report
Fierce Pharma
China
Opdivo
Repatha
Lynparza
drug approvals
Bristol-Myers Squibb
Amgen
AstraZeneca
Eli Lilly
Gilead Sciences
Flag link:

Pages